| Multicriteria decision analysis to support health technology assessment agencies: benefits, limitations, and the way forward R Baltussen, K Marsh, P Thokala, V Diaby, H Castro, I Cleemput, M Garau, ... Value in Health 22 (11), 1283-1288, 2019 | 143 | 2019 |
| Health technology assessment for molecular diagnostics: practices, challenges, and recommendations from the medical devices and diagnostics special interest group S Garfield, J Polisena, DS Spinner, A Postulka, CY Lu, SK Tiwana, ... Value in Health 19 (5), 577-587, 2016 | 39 | 2016 |
| Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence E Clay, A Khemiri, V Zah, S Aballéa, J Ruby, CV Asche Journal of Medical Economics 17 (9), 626-636, 2014 | 28 | 2014 |
| Analysis of buprenorphine/naloxone dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: a retrospective study of US public … A Khemiri, E Kharitonova, V Zah, J Ruby, M Toumi Postgraduate medicine 126 (5), 113-120, 2014 | 24 | 2014 |
| Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries K Kolasa, Z Kalo, V Zah, T Dolezal Expert Review of Pharmacoeconomics & Outcomes Research 12 (3), 283-287, 2012 | 24 | 2012 |
| How can multi criteria decision analysis support value assessment of pharmaceuticals?-findings from a systematic literature review K Kolasa, V Zah, M Kowalczyk Expert Review of Pharmacoeconomics & Outcomes Research 18 (4), 379-391, 2018 | 23 | 2018 |
| Revealed preferences towards the appraisal of orphan drugs in Poland-multi criteria decision analysis K Kolasa, KM Zwolinski, V Zah, Z Kaló, T Lewandowski Orphanet Journal of Rare Diseases 13, 1-14, 2018 | 21 | 2018 |
| Paying for Digital Health Interventions-What Evidence is Needed? V Zah, A Burrell, C Asche, Z Zrubka Acta Polytechnica Hungarica 19 (9), 179-199, 2022 | 17 | 2022 |
| How useful are digital health terms for outcomes research? An ISPOR special interest group report A Burrell, Z Zrubka, A Champion, V Zah, L Vinuesa, AP Holtorf, ... Value in Health 25 (9), 1469-1479, 2022 | 15 | 2022 |
| Future of data analytics in the era of the general data protection regulation in Europe K Kolasa, W Ken Redekop, A Berler, V Zah, CV Asche PharmacoEconomics 38 (10), 1021-1029, 2020 | 14 | 2020 |
| Budgetary impact of the utilization of buprenorphine/naloxone sublingual film and tablet for Medicaid in the United States CV Asche, E Clay, E Kharitonova, V Zah, J Ruby, S Aballéa Journal of Medical Economics 18 (8), 600-611, 2015 | 12 | 2015 |
| Healthcare costs and resource use of patients with Dupuytren contracture treated with collagenase clostridium histolyticum or fasciectomy: a propensity matching analysis V Zah, J Pelivanovic, S Tatovic, D Vukicevic, M Imro, J Ruby, D Hurley ClinicoEconomics and Outcomes Research, 635-643, 2020 | 8 | 2020 |
| Health technology assessment in Serbia D Atanasijevic, V Zah International Journal of Technology Assessment in Health Care 33 (3), 384-389, 2017 | 7 | 2017 |
| The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe: issues, trends and recommendations K Kolasa, Z Kalo, V Zah Expert Review of Pharmacoeconomics & Outcomes Research 16 (4), 483-488, 2016 | 7 | 2016 |
| Concomitant use of benzodiazepines in chronic pain patients adherent to extended-release tapentadol or oxycodone treatment—A retrospective claims analysis V Zah, M Imro, S Tatovic, SD Passik, D Vukicevic Journal of Opioid Management 16 (6), 461-479, 2020 | 5 | 2020 |
| Budget impact of introducing linagliptin into bosnia and herzegovina health insurance drug reimbursement list in 2016-2018 T Catic, L Lekic, V Zah, V Tabakovic Materia Socio-Medica 29 (3), 176, 2017 | 5 | 2017 |
| Zrx Mcdm: a fully flexible tool to support the local adaptation of multiple-criteria decision criteria in health care V Zah, S Thompson, M Berjan, R Goeree Value in Health 18 (7), A703, 2015 | 5 | 2015 |
| Budgetary impact of adding roflumilast to managed care formulary in the treatment of chronic obstructive pulmonary disease S Sun, V Zah, S Blum Med. Decis. Making, E124-E125, 2012 | 4 | 2012 |
| Accuracy of noninvasive diagnostic tests for the detection of significant and advanced fibrosis stages in nonalcoholic fatty liver disease: a systematic literature review of … D Gosalia, V Ratziu, F Stanicic, D Vukicevic, V Zah, N Gunn, ... Diagnostics 12 (11), 2608, 2022 | 3 | 2022 |
| Treatment of bypass failure in patients with chronic limb threatening ischemia–open surgery vs. percutaneous mechanical thrombectomy B Migliara, TF Cappellari, M Mirandola, A Griso, K Kolasa, V Zah, ... Vasa, 2020 | 3 | 2020 |
Carl AscheUniversity of Utah Health在 pharm.utah.edu 的电子邮件经过验证
Carl AscheUniversity of Utah Health在 pharm.utah.edu 的电子邮件经过验证
Zoltán KalóCenter for Health Technology Assessment, Semmelweis University; Syreon Res在 semmelweis.hu 的电子邮件经过验证